Immune Profiling

The overall mission of the HIV Vaccine Trials Network is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally. The Duke Laboratories as part of the HVTN Laboratory Center are utilizing state of the art technologies to comprehensively interrogate the humoral immune response to HIV vaccines to identify and characterize protective immune responses.
Provide comprehensive, state-of-the-art, humoral immunity assay services to determine quantitative and qualitative features of antibody specificity, pharmacokinetics and Fc-mediated antiviral functions. These include the evaluation of systemic and mucosal antibodies (isotypes, subclasses, forms), anti-idiotype, binding specificity and breadth (i.e. for native protein structures, virions, infected cells), and Fc Receptor (FcR)-mediated antibody functions.
The Center for AIDS Research supports a multidisciplinary environment that promotes basic, clinical, epidemiologic, behavioral, and translational research in the prevention, detection, and treatment of HIV infection and AIDS. The Duke Immunology Core provides innovative, state-of-the-art, and standardized repertoires of immunologic assays to comprehensively interrogate the immunologic space in HIV-1 infection, vaccination, co-infection and HIV-1 cure studies.

The National Institute of Allergy and Infectious Disease Vaccine and Treatment Evaluation Units (NIAID VTEUs) play a key role in the development new and improved vaccines and therapies against infectious diseases. VTEUs have run hundreds of clinical trials, many of which have contributed vaccines becoming licensed for use. A key feature of the VTEUs' success is their ability to enroll large numbers of volunteers into trials rapidly and vaccinate them in a safe, effective and quick manner.

Determining recent infection across the globe is critical to more precisely target prevention resources and determine their effectiveness. Current incidence tests have an unacceptable level of false recents and in particular have overall poor performance with difficult to classify specimens such as viremia suppressed and antiretroviral treated. Thus, new immunological biomarkers of recent infection are needed in the current setting where treatment for all, including the newly diagnosed, is standard of care.

The RBL Immunology Unit is a service component of the Regional Biocontainment Laboratory at Duke (housed in GHRB).  In addition to providing access to specialized instrumentation for Real-Time PCR, and Luminex-based multiplex assays, this unit assists investigators with design and implementation of molecular, protein, and cellular assays to quantify immune reconstitution or immune responses in vitro and in vivo.